Brokerages Set Replimune Group, Inc. (NASDAQ:REPL) Price Target at $19.43

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) has received a consensus rating of "Buy" from the eight ratings firms that are currently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $19.43.

A number of research analysts have weighed in on REPL shares. HC Wainwright raised their price objective on Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, February 13th. BMO Capital Markets raised their target price on shares of Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. lifted their price objective on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th.

Replimune Group Price Performance

Shares of NASDAQ:REPL traded up $0.01 during midday trading on Friday, reaching $7.72. 28,849 shares of the company's stock traded hands, compared to its average volume of 866,287. The company has a market cap of $594.17 million, a P/E ratio of -2.53 and a beta of 1.26. The company has a fifty day simple moving average of $11.08 and a two-hundred day simple moving average of $11.83. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. Replimune Group has a 1 year low of $4.92 and a 1 year high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Equities analysts predict that Replimune Group will post -2.97 EPS for the current fiscal year.

Institutional Investors Weigh In On Replimune Group

A number of large investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. raised its stake in Replimune Group by 12.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company's stock valued at $5,313,000 after buying an additional 52,498 shares in the last quarter. Geode Capital Management LLC raised its stake in Replimune Group by 17.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company's stock valued at $15,657,000 after acquiring an additional 217,308 shares during the last quarter. Barclays PLC lifted its position in Replimune Group by 165.5% during the 3rd quarter. Barclays PLC now owns 158,491 shares of the company's stock worth $1,738,000 after acquiring an additional 98,791 shares during the period. Victory Capital Management Inc. purchased a new position in Replimune Group during the 4th quarter worth $543,000. Finally, Swiss National Bank boosted its holdings in shares of Replimune Group by 57.4% in the fourth quarter. Swiss National Bank now owns 103,700 shares of the company's stock valued at $1,256,000 after acquiring an additional 37,800 shares in the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.